Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …

Importance Current treatment cures most cases of early-stage, primary breast cancer.
However, better techniques are required to identify which patients are at risk of relapse …

Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA
(cfDNA) requires understanding of the various biological compartments contributing to the …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA that is shed by malignant
tumors into the bloodstream and other bodily fluids. Levels of ctDNA are typically low …

PURPOSE Discordance between plasma and tumor variant calling has been attributed
primarily to tumor heterogeneity, whereas technical variables remain largely unexplored …

Background Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential
to obviate the need for some invasive biopsies in cancer patients while also elucidating …

Background Cell-free DNA (cf-DNA)-based liquid biopsy is emerging as a revolutionary new
method in individualized cancer treatment and prognosis monitoring, although detecting …

The introduction of next-generation sequencing has resulted in testing multiple genes
simultaneously to identify inherited pathogenic variants (PVs) in cancer susceptibility genes …

In the last few years, the treatment of patients with non-small cell lung cancer (NSCLC) has
impressively benefitted from immunotherapy, in particular from the inhibition of immune …